C diff....Again
No Thumbnail Available
Authors
Meeting name
Sponsors
Date
Journal Title
Format
Article
Subject
Abstract
The AHRQ commissioned a systemic review of C diff. Bottom line....vancomycin ($1300) is probably not better than metronidazole ($20); also, fidaxomicin ($3400) appears to reduce relapse vs vancomycin for non-NAP1 strains.
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
OpenAccess.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.